Age at screening (years)
|
64 (59, 67)
|
63 (59, 67)
|
65 (61, 69)
|
65 (60, 67)
|
65 (61, 68)
|
Total PSA
|
3.75 (3.12, 4.80) N = 228
|
4.23 (3.36, 5.58)
|
4.86 (3.81, 7.23)
|
-
|
-
|
Free PSA
|
0.88 (0.67, 1.15) N = 228
|
1.01 (0.77, 1.32)
|
0.96 (0.67, 1.36)
|
-
|
-
|
Intact PSA
|
0.38 (0.27, 0.56) N = 228
|
0.45 (0.34, 0.63)
|
0.50 (0.33, 0.75)
|
-
|
-
|
Human Kallikrein 2
|
0.061 (0.038, 0.094) N = 216
|
0.061 (0.036, 0.090)
|
0.088 (0.050, 0.132)
|
-
|
-
|
Number of biopsy cores
|
-
|
12 (10, 12)
|
12 (10, 12)
|
11 (6, 12)
|
10 (6, 12)
|
Clinical T Stage
| | | | | |
T1
|
-
|
-
|
31 (37%)
|
-
|
13 (41%)
|
T2
|
-
|
-
|
39 (47%)
|
-
|
12 (38%)
|
T3
|
-
|
-
|
8 (10%)
|
-
|
1 (3%)
|
Missing
|
-
|
-
|
5 (6%)
|
-
|
6 (19%)
|
Biopsy Gleason Grade
| | | | | |
<= 6
|
-
|
-
|
33 (40%)
|
-
|
17 (53%)
|
7
|
-
|
-
|
33 (40%)
|
-
|
11 (34%)
|
>= 8
|
-
|
-
|
12 (14%)
|
-
|
3 (9%)
|
Missing
|
-
|
-
|
5 (6%)
|
-
|
1 (3%)
|